The abstract is read at the publisher; the summary is JClub's.
Prediction-aided tapering of bDMARDs in rheumatoid arthritis patients with sustained low disease activity did not reduce flare rates versus DGDO over 18 months.
- Why it matters: The trial addresses whether using a dynamic model to guide tapering can lower flares compared with standard disease activity–guided dose optimisation in RA patients on stable biologics.
- What they did: In a pragmatic, multicentre, open-label randomised superiority trial, 162 patients were assigned 1:1 to DGDO alone or DGDO supported by a validated dynamic prediction model estimating 3-monthly flare risk, with 18-month follow-up.
- The result: Mean flares per patient were 1.00 (95% CI 0.73–1.27) with prediction-aided tapering and 0.73 (95% CI 0.51–0.95) with DGDO (rate ratio 1.32; 95% CI 0.90–1.95), with similar DAS28-CRP trajectories, dose reduction, patient-reported outcomes, and infection rates.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.